Rational mutagenesis to support structure-based drug design: MAPKAP kinase 2 as a case study

BACKGROUND: Structure-based drug design (SBDD) can provide valuable guidance to drug discovery programs. Robust construct design and expression, protein purification and characterization, protein crystallization, and high-resolution diffraction are all needed for rapid, iterative inhibitor design. W...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Argiriadi, Maria A, Sousa, Silvino, Banach, David, Marcotte, Douglas, Xiang, Tao, Tomlinson, Medha J, Demers, Megan, Harris, Christopher, Kwak, Silvia, Hardman, Jennifer, Pietras, Margaret, Quinn, Lisa, DiMauro, Jennifer, Ni, Baofu, Mankovich, John, Borhani, David W, Talanian, Robert V, Sadhukhan, Ramkrishna
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: BioMed Central 2009
Pynciau:
Research Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC2678131/
https://ncbi.nlm.nih.gov/pubmed/19296855
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1472-6807-9-16
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg